# Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

> **NCT00600054** · PHASE2 · COMPLETED · sponsor: **YM BioSciences** · enrollment: 44 (actual)

## Conditions studied

- Recurrent Diffuse Pontine Gliomas

## Interventions

- **BIOLOGICAL:** nimotuzumab (anti EGFR humanized monoclonal antibody)

## Key facts

- **NCT ID:** NCT00600054
- **Lead sponsor:** YM BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-03
- **Final completion:** 2010-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2011-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600054, "Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00600054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*